"SILVER SPRING, MD â€” A US Food and Drug Administration (FDA) advisory committee has given its blessing to a new injectable that combines fixed doses of a long-acting basal insulin with a glucagonlike peptide 1 (GLP-1) receptor agonist for diabetes"...
No reports of overdosage with GlucaGen® have been reported. If overdosage occurs, the patient may experience nausea, vomiting, inhibition of GI tract motility, increase in blood pressure and pulse rate. In case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed. If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.
GlucaGen® is contraindicated in patients with:
Last reviewed on RxList: 2/16/2016
Additional GlucaGen Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find tips and advances in treatment.